198 related articles for article (PubMed ID: 37154682)
1. Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.
Flanagan S; Walker H; Ong V; Sandison T
Microbiol Spectr; 2023 Jun; 11(3):e0133923. PubMed ID: 37154682
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
Flanagan S; Ong V; Marbury T; Jandourek A; Gandhi RG; Sandison T
Pharmacotherapy; 2024 Jun; 44(6):435-443. PubMed ID: 38840536
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and
Miesel L; Cushion MT; Ashbaugh A; Lopez SR; Ong V
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318018
[TBL] [Abstract][Full Text] [Related]
4. Rezafungin: a novel antifungal for the treatment of invasive candidiasis.
Ham YY; Lewis JS; Thompson GR
Future Microbiol; 2021 Jan; 16(1):27-36. PubMed ID: 33438477
[TBL] [Abstract][Full Text] [Related]
5. Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects.
Flanagan S; Goodman DB; Jandourek A; O'Reilly T; Sandison T
Clin Pharmacol Drug Dev; 2020 May; 9(4):456-465. PubMed ID: 31793231
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181375
[TBL] [Abstract][Full Text] [Related]
7. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson GR; Soriano A; Honore PM; Bassetti M; Cornely OA; Kollef M; Kullberg BJ; Pullman J; Hites M; Fortún J; Horcajada JP; Kotanidou A; Das AF; Sandison T; Aram JA; Vazquez JA; Pappas PG
Lancet Infect Dis; 2024 Mar; 24(3):319-328. PubMed ID: 38008099
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.
Rubino CM; Flanagan S
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084221. PubMed ID: 34398673
[TBL] [Abstract][Full Text] [Related]
10. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.
Miesel L; Lin KY; Ong V
Pharmacol Res Perspect; 2019 Dec; 7(6):e00546. PubMed ID: 31763045
[TBL] [Abstract][Full Text] [Related]
11. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
[TBL] [Abstract][Full Text] [Related]
12. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy.
Sofjan AK; Mitchell A; Shah DN; Nguyen T; Sim M; Trojcak A; Beyda ND; Garey KW
J Glob Antimicrob Resist; 2018 Sep; 14():58-64. PubMed ID: 29486356
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
[TBL] [Abstract][Full Text] [Related]
14. Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481440
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model.
Hager CL; Larkin EL; Long LA; Ghannoum MA
J Antimicrob Chemother; 2018 Aug; 73(8):2085-2088. PubMed ID: 29897469
[TBL] [Abstract][Full Text] [Related]
16. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
17. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR; Soriano A; Cornely OA; Kullberg BJ; Kollef M; Vazquez J; Honore PM; Bassetti M; Pullman J; Chayakulkeeree M; Poromanski I; Dignani C; Das AF; Sandison T; Pappas PG;
Lancet; 2023 Jan; 401(10370):49-59. PubMed ID: 36442484
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.
Roepcke S; Passarell J; Walker H; Flanagan S
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0091623. PubMed ID: 38014945
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.
Lakota EA; Ong V; Flanagan S; Rubino CM
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555631
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers.
Lesko LJ; Offman E; Brew CT; Garza D; Benton W; Mayo MR; Romero A; Du Mond C; Weir MR
J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):434-446. PubMed ID: 28585859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
